Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Clinical trial NCT05657860 · COMPLETED

Trial details

NCT number: NCT05657860
Sponsor: Maimonides Medical Center
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Prader-Willi Syndrome Aggression Self-Injurious Behavior Pathologic Processes Behavioral Symptoms Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders

Start date: 2020-12-17
Primary completion: 2023-12-16
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.